SET domain bifurcated protein 1 (SETDB1) is a human histone-lysine methyltransferase, which is amplified in human cancers and was shown to be crucial in the growth of non-small and small cell lung carcinoma. In addition to its catalytic domain, SETDB1 harbors a unique tandem tudor domain which recognizes histone sequences containing both methylated and acetylated lysines, 2 and likely contributes to its localization on chromatin. Using X-ray crystallography and NMR spectroscopy fragment screening approaches, we have identified the first small molecule fragment hits that bind to histone peptide binding groove of the TTD of SETDB1. Herein, we describe the binding modes of these fragments and analogues and the biophysical characterization of key compounds. These confirmed small molecule fragments will inform the development of potent antagonists of SETDB1 interaction with histones.
INTRODUCTION
Post-translational modifications (PTMs) such as methylation, phosphorylation, acetylation, ubiquitination, and SUMOylation of histone proteins impact gene expression by altering chromatin compaction or recruiting effector proteins. [1] [2] [3] Methylation of histones occurs predominantly at the lysine and arginine sidechains of histone 3 (H3K4, H3K9, H3K27, H3K36, H3K79 and H3R2) and histone 4 (H4K20 and H4R3). Unlike some other PTMs, methylation of a lysine or arginine sidechain does not change overall charge but results in subtle alterations in size and hydrophobicity, which can influence chromatin packing. 4 Transcriptional activation or repression is dependent on the position and degree of methylation 5 and aberrant methylation of histones can result in dysregulation of cell growth and development of cancer. 6 Many of the histone methyl transferases have been extensively studied and selective inhibitors have been effective in preclinical models. [7] [8] [9] Human SETDB1 is a histone-lysine methyltransferase (HMT), which specifically trimethylates histone H3 lysine 9 (H3K9me3). It is therefore deemed central in the silencing of specific euchromatic genes. 10 Recent studies have also suggested that SETDB1 could be an oncogene. Its overexpression is crucial to the growth of non-small and small cell lung cancer cell lines and has been reported in various human cancers. [11] [12] [13] Overexpressed SETDB1 increases H3K9me3 leading to alterations in gene expression.
14 SETDB1 contains a tandem tudor domain (TTD), a methyl-DNA binding domain (MBD), and a SET domain. 15 The MBD of SETDB1 promotes direct binding to methylated DNA sites and mediates trimethylation of H3K9 in a site-directed fashion. The SET domain catalytically "writes" the epigenetic methyl mark, which then goes on to recruit proteins belonging to the Heterochromatin Protein 1 (HP1) family to control gene repression. 10 Tudor domains are associated with the recognition of different methylation levels of lysine and arginine residues and the TTD of SETDB1 has been associated with the recognition of di-and trimethylation states of H3K9. 16, 17 To the best of our knowledge, and despite the evident therapeutic importance of SETDB1, no antagonists of this protein have been reported to date. We therefore undertook fragment based approach toward discovery of ligands for SETDB1. We successfully crystallized the truncated tandem tudor domain of SETDB1 in complex with a histone 3 peptide dimethylated at lysine 9 and acetylated at lysine 14 (H3K9me2K14ac). 18 The co-crystal structure shows that 6BHD.
We used a crystal soaking fragment screening approach to identify small-molecule ligands occupying the Kme and/or Kac pockets of SETDB1-TTD. Crystal structures revealed binding modes that could enable structure-guided hit optimization toward the development of SETDB1
antagonists.
RESULTS AND DISCUSSIONS
Hit Identification. In order to identify small molecule antagonists of SETDB1-TTD, we screened a fragment library of 252 compounds by soaking the apo crystals of SETDB1-TTD with pools of 3 compounds and identified a single fragment hit (1) . Co-crystal structure of 1 with SETDB1-TTD revealed that it binds in the Kme pocket ( Figure 2 ). However, fragment 1 did not show any HSQC shift at concentrations as high as 10 mM, indicating very weak binding.
As a major part of the H3K9me2K14ac peptide occupies and forms hydrogen bonding interactions in and around the Kac pocket, fragments binding in the Kac pocket are likely to have higher ligand efficiency and can potentially be optimized to improve affinity. To test this hypothesis, we selected and soaked 5 constrained analogues of known bromodomain inhibitors 19 synthesized in our laboratory (Supplementary Figure 1) . Bromodomain inhibitors are known acetyl lysine mimics 20 and could potentially bind to the Kac pocket of the SETDB1-TTD. Out of 5 fragments, one fragment (2) was found to bind to SETDB1-TTD occupying the TTD Kac pocket ( Figure 2 ). Binding of 2 to SETDB1-TTD was also confirmed by HSQC NMR at 5mM
(Supplementary Figure 2) . In order to explore the SAR of these hits and assess the feasibility of improving their activity, a small set of analogs was synthesized and tested by HSQC NMR and/or by SPR. 
Chemistry
The tricyclic triazole 2 was prepared from commercially available 2-aminobenzyl alcohol (11), which was reacted with ethylchloroacetate (12) in the presence of sodium hydride to give the lactam. Treatment of the lactam with Lawesson's reagent led to the corresponding thioamide 13, which was subsequently condensed with acethydrazide (14) to give the desired tricycle 2 in 6% yield overall yield (Scheme 1). accomplished with hydrochloric acid in methanol and the free amine was treated with acetic anhydride or with methanesulfonyl chloride in the presence of base to yield the corresponding acetamide 5 and sulfonamide 7, respectively. After the deprotection of triazole 27 under the same conditions, the free amine of the crude product was treated with triphosgene followed by methylamine to give 6. The corresponding triazole carboxylic acid 8 was prepared by reacting 28 with acethydrazide. Halogenation of 25 with NBS and NCS gave 29a and 29b, respectively. Following the same protocol for converting 25 into 5 (Scheme 4), the corresponding halogenated intermediates 29a and 29b were converted to 9a and 9b. Palladium-catalyzed cyanation of 9a gave 9c, and Suzuki coupling of 9a with the corresponding boronic acids gave 9d and 9e. The peptide intermediate 40 for the synthesis of 10 was synthesized from peptide 38, which was in turn obtained using a standard 2-chlorotrityl resin protocol. Hydrogenolysis of the Cbz group of 38 followed by dimethylation via reductive amination of the lysine side chain with formaldehyde gave peptide 40 in 85% yield over two steps (Scheme 6). Coupling of the acid 40 with the amine 37 was followed by deprotection of Boc and t Bu groups with TFA to give 10 (Scheme 7). figure 3) and synthesized 3 amides, extending fragment 1 in the desired direction. Ligand-protein interactions were assessed using HSQC NMR as a first pass screen. None of the 22 analogs tested showed HSQC NMR shift at 10 mM. However, we were able to obtain the co-crystal structure of 3 with SETDB1-TTD, wherein the tetrahydroisoquinoline core of 3 occupies the aromatic cage of the Kme pocket, and the amide extends towards the Kac pocket (Figure 3c) . No electron density was observed for the furan group, indicating suboptimal interactions with the protein. As none of the analogs of 1 showed any significant activity, we turned our focus toward identifying fragments that occupy the Kac pocket. We also synthesized the corresponding urea 6, sulfonamide 7, and carboxylic acid 8 ( Figure 5 ).
All three compounds were predicted to form additional or alternate hydrogen bonds with the protein, however, only the sulfonamide analog 7 showed a strong HSQC NMR shift at 5 mM (Supplementary Figure 2) and affinity comparable to 5 by ITC ( Figure 5 ) and SPR.
(Supplementary Figure 4) (Kd = 4mM -17mM in both assays). Despite forming a number of hydrogen bonding interactions with the protein, 5 showed only weak binding by ITC and SPR, which is likely due to incomplete occupation of the large pocket that is occupied by the native peptide H3K9me2K14ac. We therefore decided to grow the fragment 5 into the pocket occupied by the peptide. We initially focused on simple substitutions at the para position of the phenyl ring of 5 to rescue hydrophobic interactions observed between 2 and I333. However, none of the para-substituted analogues showed significant improvement of binding compared to 5 as measured by SPR (Table 1 and Supplementary Figure 4) . Biophysical assays. Isothermal titration calorimetry (ITC) for 5 was performed at 25 °C using Nano ITC instrument (TA Instruments, USA). The cell was loaded with 80 µM SETDB1 (Tudor domain) in 20 mM HEPES pH 7.5 and 250 mM NaCl. The syringe was loaded with 100 mM compound 5 dissolved in the same buffer (pH was checked and no DMSO was used). 25
injections of 2 µL volumes were applied at 180 s intervals. "Nano Analyze" software package (supplied by the manufacturer) was used for data analysis. The data was fit to a one binding site model.
ITC for compound 7 was performed using the same instrument and using similar conditions as for compound 5. The cell was loaded with 98 µM SETDB1 in 20 mM HEPES pH 7.5 and 250 mM NaCl. The syringe was loaded with 50 mM compound 7 (It was not possible to prepare 100 mM solution due to limited solubility) dissolved in the same buffer as protein (again pH was checked and no DMSO was used).
NMR spectroscopy. 1H-15N HSQC-TROSY spectra were collected at 298 K on 500 MHz
Bruker Avance spectrometer equipped with 1. The solvent was evaporated in vacuo and the crude product was redissolved in EtOAc, washed subsequently with water, saturated sodium thiosulfate, water and brine and dried over sodium sulfate. The crude product was then purified by column chromatography. 
1-methyl-4H,6H-benzo

tert-butyl (2-acetamidobenzyl)carbamate (25).
2-Aminobenzylamine (3.0 g, 24.6 mmol) was dissolved in 50 mL of dry THF. Triethylamine (3.8 mL, 27.2 mmol) was added to the solution followed by Boc2O (5.4 g, 24.6 mmol). The mixture was stirred overnight at room temperature under a N2 atmosphere. The reaction mixture was poured into a 10% citric acid solution (25 mL) and extracted with EtOAc (2 x 50 mL). The combined organics were washed with brine (25 mL), dried over MgSO4, filtered and concentrated to give 24 as a white solid in 99% yield (5.41 g, 24.3 mmol). In a flame dried round-bottom flask, tert-butyl(2-aminobenzyl)carbamate 24 (1.5 g, 6.75 mmol) was dissolved in DCM (13.5 mL) and acetic anhydride (0.7 mL, 7.43 mmol) was added to the solution at 0 ºC and allowed to warm to room temperature. After 2 hours, the reaction reached completion by TLC. 
1-(2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)benzyl)-3-methylurea (6). After Boc deprotection of
27 using general procedure B, the free amine (0. 
N-(2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)benzyl)methanesulfonamide (7)
. After Boc deprotection of 27 using general procedure B, free amine (1.0 equiv., 48 mg, 0.237 mmol) and triethylamine (1.2 equiv., 39.7 µL, 0.285 mmol) were dissolved in anhydrous dichloromethane (2.4 mL, 0.1 M) in an oven-dried 2-dram vial equipped with magnetic stir bar and rubber septum.
The resulting mixture was cooled to 0 ºC and then methanesulfonyl chloride (1.2 equiv., 22 µL, 0.285 mmol) was added. After stirring at 0 ºC for 1 hour, the reaction was warmed to room temperature over 2 hours and then quenched with 5 mL of a saturated solution of sodium bicarbonate. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3x5 mL). The organic extracts were combined, dried over sodium sulfate, filtered, and solvent was removed in vacuo. The crude residue was then purified by reverse-phase 
2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)benzoic acid (8).
Anhydride 28 21 (1.0 g, 6.21 mmol, 1.1 equiv.) and acetylhydrazide (418 mg, 5.64 mmol, 1.0 equiv.) were refluxed in EtOH (56 mL, 0.1M) for 3 h. 22 The reaction was cooled down to r.t. and then dry loaded on celite. The crude was purified using C18 functionlized silica gel using a gradient from 5:95 MeCN:H2O to 1: 
tert-butyl (5-bromo-2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)benzyl)carbamate (31a).
Synthesized according to general procedure C. The reaction was diluted with chloroform and washed with water and brine and solvent was removed in vacuo and the crude product was purified by column chromatography . 
2-(3-(((tert-butoxycarbonyl)amino)methyl)-5-methyl-4H-1,2,4-triazol-4-yl)benzoic acid (33).
Anhydride 28 (2.65 g, 16.4 mmol, 1.0 equiv.) 21 and hydrazide 32 ( mg, mmol, 1.2 equiv.) 22 were refluxed EtOH for 3 hours . 23 The reaction was cooled down to room temperature and the reaction was dry loaded in celite and purified on C18 functionalized silica column using a gradient and purified using C18 functionalized silica using a gradient from 0: 
